is associated with a lower relapse rate than azathioprine when used for remission maintenance after remission induction with cyclophosphamide Different doses of rituximab have been used for remission maintenance, including IV 500 mg every 6 months  (FDA-approved), IV 1,000 mg every 4 months If methotrexate or azathioprine treatment is being considered for remission maintenance, the patient's clinical situation, preferences, and values should guide selection between them, given their comparable